KymaThera Raises $80M to Advance K-1728 Into the Clinic

KymaThera has raised an $80 million Series B to move K-1728, its oral pan-mutant selective PI3Kα inhibitor, into human testing. The financing is not a bet on whether PI3Kα matters. Approved medicines have already validated the target. It is a bet that more deliberate mutation coverage and less wild-type inhibition can produce a better therapeutic window.

That distinction matters because K-1728 is entering a field with known biology, meaningful clinical precedent and persistent tradeoffs. KymaThera now has the capital to test whether its preclinical design translates into dose, tolerability and antitumor activity in patients.

What Happened

KymaThera announced the financing on October 6, 2026. Alta Partners led the Series B, with existing investors Venrock and Foresite Capital, new investor J. Wood Capital and other participants. The company says the round brings its total capital raised above $100 million.

The proceeds are intended to advance K-1728 through initial clinical proof-of-concept. KymaThera expects to begin dosing patients in a Phase 1 study in the fourth quarter of 2026, making the next stage of the company less about molecule design in isolation and more about clinical translation.

KymaThera was founded in 2024 and is based in San Diego. The company describes its approach as structure-based drug discovery focused on precision medicines. K-1728 is its lead and wholly owned program.

Why K-1728 Exists

PI3Kα helps regulate cellular growth and metabolism. Disease-driving mutations in PIK3CA can activate that pathway in cancer and in a group of nonmalignant conditions known as PIK3CA-related overgrowth spectrum, or PROS. The target is therefore relevant across distinct diseases, but the molecular problem is similar: suppress aberrant signaling while preserving enough normal PI3Kα function to support tolerable dosing.

The challenge is visible in the existing treatment landscape. FDA records show that PI3Kα inhibition is clinically validated in PROS, while PIK3CA-directed therapies also have approved roles in advanced HR-positive/HER2-negative breast cancer. At the same time, clinical guidance identifies hyperglycemia as an important effect associated with PI3Kα inhibition.

KymaThera designed K-1728 to inhibit both kinase-domain and helical-domain mutant forms of PI3Kα while sparing the wild-type enzyme. In principle, that could broaden the mutations addressed without forcing normal PI3Kα biology to become the limiting factor for dose. That is the program's central hypothesis, not an established clinical result.

The company reports that K-1728 produced tumor regressions at low, once-daily doses across both mutation classes in preclinical models. It also reports a wide exposure window between tumor-regression activity and levels associated with hyperglycemia in those models. These findings have not yet demonstrated safety or efficacy in people.

One Molecule, Two Disease Settings

KymaThera's pipeline initially places K-1728 in two settings. In HR-positive/HER2-negative breast cancer, the company plans to study the candidate as a monotherapy and in combinations. In PI3Kα-driven vascular malformations, it plans monotherapy development.

Those populations differ in disease course, treatment goals and clinical endpoints. Cancer development will have to establish antitumor activity and a combination strategy in a competitive field. Vascular malformation development will have to show that pathway control can deliver meaningful benefit with a tolerability profile suitable for a nonmalignant condition.

The common thread is mutation selectivity. If the molecule can cover important PIK3CA mutations while limiting wild-type inhibition, the same design principle could matter in both settings. The Phase 1 program will begin to show whether that mechanistic logic survives contact with human pharmacology.

The Team and Capital Behind the Bet

KymaThera's leadership team combines large-pharma and biotechnology drug-discovery experience. Founder and CEO Rob Kania spent more than 20 years at Pfizer and later led research at Kinnate Biopharma. Founder and CSO Jason Cox previously worked at Merck and Kinnate. Co-founders Brooke Grandinetti and Shawn Ouyang bring discovery biology and medicinal chemistry experience from companies including Vertex, Novartis, Amgen and ImClone.

That background is central to the investor case. Alta Partners' Bob More said the investment began with the people. Foresite Capital's Michael Rome emphasized the appeal of a wholly owned asset, while Venrock's Mariana Mihalusova pointed to what the team built in roughly two years.

The syndicate is funding an experienced group through a recognizable inflection point. It gives KymaThera room to manufacture clinical supply, execute the first-in-human study and seek an early proof-of-concept signal without immediately returning to market for another round.

What the Series B Must Prove

The most important questions now move from preclinical models to patients. Investigators will need to understand dose escalation, pharmacokinetics, target engagement, safety and the incidence and severity of metabolic effects. They will also need to see whether activity extends across the mutation classes K-1728 was designed to cover.

The vascular malformation program adds a separate bar. A treatment for a chronic, nonmalignant disease may face different expectations for duration and tolerability than an oncology drug, even when both programs are built around the same pathway. Results in one setting will inform the other, but they will not substitute for indication-specific evidence.

KymaThera's $80 million Series B buys the opportunity to answer those questions. It does not answer them in advance. The next meaningful evidence will come from whether K-1728's proposed selectivity produces a usable human therapeutic window and whether that window is wide enough to support the company's plans across cancer and vascular malformations.